

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1131 mL	5.5653 mL	11.1307 mL
5 mM	0.2226 mL	1.1131 mL	2.2261 mL
10 mM	0.1113 mL	0.5565 mL	1.1131 mL
50 mM	0.0223 mL	0.1113 mL	0.2226 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin's Lymphoma[J]. Cancer Research, 2024, 84(7_Supplement): ND05-ND05.

Paolo Caimi, et al. Abstract PO-010: Trial in Progress: Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood Cancer Discov. 2024. 5 (3_Supplement): PO-010.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481